Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Pliant Therapeutics Inc’s stock clocked out at $1.38, up 0.73% from its previous closing price of $1.37. In other words, the price has increased by $0.73 from its previous closing price. On the day, 1.2 million shares were traded.
Ratios:
To gain a deeper understanding of PLRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.03 and its Current Ratio is at 11.03. In the meantime, Its Debt-to-Equity ratio is 0.23 whereas as Long-Term Debt/Eq ratio is at 0.23.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 17 ’25 when Coulie Bernard sold 52,419 shares for $11.20 per share. The transaction valued at 587,150 led to the insider holds 430,517 shares of the business.
Cummings Keith Lamont sold 20,148 shares of PLRX for $225,680 on Jan 17 ’25. The Chief Financial Officer now owns 262,608 shares after completing the transaction at $11.20 per share. On Jan 17 ’25, another insider, Hull Hans, who serves as the Chief Business Officer of the company, sold 15,936 shares for $11.20 each. As a result, the insider received 178,501 and left with 211,558 shares of the company.
Stock Price History:
Over the past 52 weeks, PLRX has reached a high of $16.10, while it has fallen to a 52-week low of $1.10. The 50-Day Moving Average of the stock is -6.18%, while the 200-Day Moving Average is calculated to be -84.90%.
Shares Statistics:
A total of 61.39M shares are outstanding, with a floating share count of 54.10M. Insiders hold about 13.48% of the company’s shares, while institutions hold 85.31% stake in the company.
